Start free trial
Trending New Genres Authors
EnglishEnglish
EspañolSpanish
简体中文Chinese
繁體中文Chinese (Traditional)
FrançaisFrench
DeutschGerman
日本語Japanese
PortuguêsPortuguese
ItalianoItalian
한국어Korean
РусскийRussian
NederlandsDutch
العربيةArabic
PolskiPolish
हिन्दीHindi
Tiếng ViệtVietnamese
SvenskaSwedish
ΕλληνικάGreek
TürkçeTurkish
ไทยThai
ČeštinaCzech
RomânăRomanian
MagyarHungarian
УкраїнськаUkrainian
IndonesiaIndonesian
DanskDanish
SuomiFinnish
БългарскиBulgarian
עבריתHebrew
NorskNorwegian
HrvatskiCroatian
CatalàCatalan
SlovenčinaSlovak
LietuviųLithuanian
SlovenščinaSlovenian
СрпскиSerbian
EestiEstonian
LatviešuLatvian
فارسیPersian
മലയാളംMalayalam
தமிழ்Tamil
اردوUrdu
Searching...
SoBrief
The Great Prostate Hoax

The Great Prostate Hoax

How Big Medicine Hijacked the PSA Test and Caused a Public Health Disaster
A cancer test finds more tumors, not necessarily lives saved. How did it become routine?
by Richard J. Ablin 2014 272 pages
4.49
115 ratings
Listen
Immersive
V2.3
Amazon Kindle Audible
Try Full Access for 3 Days
Unlock listening & more!
Continue

Key Takeaways

Treat PSA as a prostate signal, not a cancer verdict.

A noisy biological signal. Prostate-specific antigen, or PSA, is a protein made by prostate tissue that helps liquefy semen. The blood test measures a tiny amount of it, but benign enlargement, inflammation, recent ejaculation, and other factors can raise the reading. Ablin’s central distinction is that PSA is specific to the prostate, not to cancer: it appears in normal, enlarged, and cancerous prostates. A man can have cancer with a reading of 0.5 ng/mL, while another can reach 11 ng/mL without cancer.

A reading is not a diagnosis. The book argues that no single cutoff separates cancer from no cancer. PSA can still help monitor men already diagnosed or treated, but routine screening of healthy men treats an ambiguous signal as if it were a verdict.

Analysis

A test can be associated with a disease without identifying that disease in an individual. That distinction is easy to lose when a result arrives as a precise number, especially when the next clinical step is already familiar. The useful question is not simply whether PSA correlates with prostate conditions, but whether acting on the result improves outcomes enough to justify the consequences. The book’s strong criticism applies most clearly to automatic screening pathways, rather than proving that every use of PSA lacks value.

Weigh small possible gains against the cascade they trigger.

Benefits and harms together. Ablin cites two major screening studies published in 2009 as finding little or no reduction in prostate cancer deaths from PSA-based screening. He also presents health-policy specialist Peter Bach’s estimate: among 50 men whose PSA tests lead to biopsy, diagnosis, and treatment, one might avoid a prostate cancer death over the following years, while 49 would be treated for cancers that would never threaten their lives.

The downstream count matters. Psychologist Hal Arkes illustrated the trial results with two groups of 1,000 men: eight in each group died of prostate cancer, while the screened group also included men who underwent unnecessary surgery and experienced lasting complications. The exact estimates depend on the studies and assumptions being considered, but the book’s point is that counting detected cancers alone misses the costs of testing.

Analysis

This is a decision-theory problem, not a contest between caring about cancer and dismissing it. Screening can help a small number while exposing many more people to follow-up procedures, anxiety, and treatment harms. Absolute effects make that tradeoff clearer than relative risk reductions, which can sound impressive without showing how many people benefit. The estimates in the book are tied to particular studies and time periods, so they should be read as evidence for examining the balance, not as a universal forecast for every man.

Separate harmless tumors from dangerous ones before choosing treatment.

Two different disease paths. Ablin uses a turtle and a rabbit to describe the clinical problem: some prostate cancers grow so slowly that they never cause trouble, while others spread and threaten life. PSA cannot reliably tell which kind is present. The book notes that prostate cancer becomes increasingly common with age, yet most men with localized disease die of something else. Detecting more tumors therefore does not automatically mean finding more lethal ones.

Observation can be active care. Active surveillance means monitoring a diagnosed cancer with examinations and tests, reserving treatment for signs of change. The PIVOT study compared surgery with observation for localized prostate cancer and, after at least 12 years, found no significant reduction in overall or prostate cancer mortality from surgery. The book argues that a diagnosis should not automatically lead to removal of the prostate.

Analysis

The key distinction is between finding an abnormality and predicting its future behavior. When a screening tool cannot sort low-risk from high-risk disease, more detection may mostly increase the number of people living with a cancer label. Active surveillance offers a way to respond to uncertainty without pretending it has disappeared. At the same time, surveillance is not neglect: it depends on follow-up and a willingness to act if risk changes. The choice is therefore not simply treatment versus doing nothing.

Slow fear-driven decisions with time and a second opinion.

The diagnosis can accelerate everything. The book opens with John, a healthy 51-year-old whose slightly elevated PSA led to biopsy and a localized cancer diagnosis. Frightened by the word cancer, he chose prostate removal. The operation controlled the diagnosed disease, but left him incontinent and impotent. His story shows how quickly a screening result can become a life-changing intervention before a patient has understood the likely course of the disease or considered alternatives.

A pause can change the path. George Sugarman was also urged toward surgery after a biopsy found a very small amount of low-grade cancer. A second urologist suggested observation instead. Sugarman canceled the operation, and a later biopsy found no cancer. The episode does not prove that every similar diagnosis is harmless. It shows why time, a second opinion, and a clear account of options can matter before an irreversible procedure.

Analysis

Fear narrows attention toward the worst imaginable outcome and makes immediate action feel safer than measured uncertainty. In this setting, a pause is not an argument for ignoring a diagnosis. It is a way to make room for prognosis, treatment effects, and alternatives to enter the decision. A second opinion can also expose how much a recommendation depends on a clinician’s specialty or experience. The patient still faces uncertainty, but no longer has to mistake urgency for evidence.

A weak test became a mass market when promotion outran evidence.

A change in intended use. Ablin discovered PSA in 1970 as a prostate tissue marker. Hybritech developed a blood test and, in 1986, received FDA approval to use it in managing men already diagnosed with prostate cancer. The book describes how PSA soon spread into screening healthy men, a much larger market, before the evidence established that screening improved survival. In 1994, the FDA approved the test as an aid in early detection.

Regulation did not end the debate. At FDA advisory meetings, panelists questioned the evidence, the test’s false-positive rate, and the risk that screening would lead to unnecessary biopsies and treatment. Ablin says the 1993 panel recommended conditions that did not make it into the final approval. His account presents the regulatory history as a failure to distinguish a product’s approved use from its expanding use in everyday practice.

Analysis

A device’s original indication and its real-world role can diverge sharply once clinicians, marketers, and patients adopt it. Approval for one purpose does not itself establish benefit for another, especially when the new use reaches a far larger population. The book makes a forceful case that oversight lagged behind that shift. Financial relationships and institutional incentives deserve scrutiny, but they do not by themselves prove that every clinician or company acted in bad faith. The strongest lesson concerns the system’s capacity to challenge unsupported use.

Earlier diagnosis can inflate survival statistics without extending life.

The clock can mislead. Lead-time bias occurs when finding a disease earlier makes the measured time from diagnosis to death longer, even if the person dies at the same age. Overdiagnosis adds another distortion: screening finds abnormalities that meet the definition of cancer but would never cause symptoms or death. Both effects can make screening appear more successful when judged by survival after diagnosis.

More detection is not proof of rescue. The book contrasts higher five-year survival figures reported in the United States with lower figures in the United Kingdom, while noting that prostate cancer mortality was similar. More screening in the United States meant more early diagnoses, including slow-growing tumors. Ablin argues that this can make survival statistics look better without showing that men lived longer. The more relevant question is whether screening reduces deaths or serious illness in comparable groups.

Analysis

This distinction is a reminder to match a measure to the question being asked. Survival after diagnosis is not the same outcome as living longer, just as detecting more disease is not equivalent to preventing deaths. Public messaging often favors the first, more intuitive measure. Mortality and quality-of-life outcomes are harder to communicate, but they better capture whether an intervention changes a person’s life rather than the calendar attached to a diagnosis.

Demand comparative evidence before buying high-tech cancer care.

Newer is not automatically better. The book examines proton-beam therapy and the da Vinci robotic surgical system as expensive technologies promoted for prostate cancer. A proton facility could cost more than $200 million to build; the book cites Medicare payments of about $32,000 for proton treatment compared with $18,000 for standard X-ray radiation. The studies it discusses found no clear advantage in outcomes or side effects for prostate cancer patients.

Marketing can outrun comparison. Robotic prostate surgery was promoted as less invasive and more protective of sexual and urinary function. Yet the studies cited by Ablin found no reliable advantage in those feared complications over open surgery. The technology may have some practical benefits, such as shorter hospital stays or fewer transfusions, but those claims do not establish that it improves the outcomes patients care about most.

Analysis

A sophisticated machine can make a treatment look precise, modern, and therefore superior. That impression is not a substitute for comparing patient outcomes, side effects, and costs against existing options. The book’s criticism is strongest when it asks whether the added expense buys a measurable benefit. It is less useful to treat technology itself as the villain: a costly innovation may be worthwhile when evidence supports it. The standard should be demonstrated value, not visual drama or novelty.

Count treatment’s bodily and financial costs, not just the test.

A small test can open a long pathway. A PSA result may lead to biopsy, a cancer diagnosis, surgery or radiation, and treatment for resulting problems. Ablin describes men left with incontinence or erectile dysfunction, sometimes requiring pads, medications, or further operations. These outcomes are not minor to the people living with them, and they also create continuing costs for families and the health system.

Incentives shape the pathway. The book cites a study of 36,261 biopsies in which urologists with a financial interest in pathology testing billed for 4.3 more specimens per biopsy on average than physicians without that interest, a 72 percent difference. This finding does not establish that every self-referral is improper. It does show why financial arrangements should be visible when clinicians recommend tests and procedures that generate revenue for their own practices.

Analysis

The familiar price of a blood test can hide the much larger expected cost of what follows. A full accounting should include physical consequences, lost function, additional care, and the chance that treatment was unnecessary. The study of self-referral makes incentives concrete, but its finding should not be stretched into a claim about every individual doctor. Transparent billing and independent review help distinguish a structural risk from an accusation of personal misconduct.

Consent starts before the needle. Ablin argues that men were often screened without being told what an elevated result could lead to, or how uncertain the benefits were. In the book, physician Daniel Merenstein discussed screening risks with a patient who declined a PSA test. After another doctor later ordered one and the patient developed advanced cancer, a jury awarded $1 million against Merenstein’s residency program. Merenstein said the case made him order more tests and discuss risks less freely.

Automatic habits are not informed choices. The American Urological Association moved toward more cautious guidelines in 2013, recommending discussion of potential harms for men in the main screening age group and against screening older men. The book’s practical demand is shared decision-making: explain the test’s limits, possible next steps, potential harms, and alternatives before ordering it.

Analysis

Consent is meaningful only when it arrives before the patient is committed to a cascade. A signature or a brief exchange cannot replace a conversation about what a result can and cannot establish. The Merenstein episode also shows how litigation risk can push clinicians toward defensive testing, even when the evidence is uncertain. Good shared decision-making protects the patient’s agency while giving the clinician a disciplined way to explain uncertainty rather than hiding behind a routine order.

Require clean trial evidence before believing a promising cancer therapy.

A plausible mechanism is not enough. The book turns to Provenge, an immune-based treatment for men with advanced prostate cancer. A 2007 FDA advisory panel supported its safety and voted that its trial data showed effectiveness, but the FDA asked for more conclusive evidence. Provenge received approval in 2010 after a later trial reported that treated men lived about 4.1 months longer than the control group.

A disputed critique remains a hypothesis. Researcher Marie Huber questioned whether differences in how white blood cells were collected and returned to the control group might have affected the survival result. Dendreon and other researchers disputed her interpretation, and the book does not establish it as fact. Ablin calls for independent examination. The episode reinforces his wider concern: when patients are desperate and commercial stakes are high, scrutiny of trial design and control procedures matters.

Analysis

The Provenge story illustrates why both enthusiasm and skepticism need evidentiary discipline. A biological rationale and a survival signal can justify attention, but questions about trial conduct must be evaluated with transparent data rather than dismissed because they are uncomfortable. Conversely, a post-trial critique is not proof that a treatment harmed patients. The right response is independent replication and careful review, especially when the people evaluating a therapy may also have financial or professional interests in its success.

Analysis

The book is a polemical history of a medical test that became a public health policy. Its structure moves from one fictionalized patient’s journey through PSA testing, biopsy, and surgery to the scientific history of the marker, FDA decisions, commercial incentives, and accounts from men living with treatment consequences. That movement gives an abstract debate a human scale: the central unit of analysis is not the test result, but the chain of choices it can set in motion.

The argument is strongest when it separates detection from diagnosis, diagnosis from prognosis, and survival statistics from actual mortality. Those distinctions explain why a test can find more abnormalities without reliably identifying dangerous disease or improving life expectancy. The book also makes a useful institutional point: screening is not a neutral act when each result creates downstream work, costs, and risks.

Its limits matter. Ablin writes as both a scientist with deep knowledge of PSA and a participant in the story of its discovery. That proximity supplies valuable history, but it can also intensify the book’s accusatory framing. Financial conflicts deserve disclosure and investigation, yet an association between profit and practice does not establish the motives behind every clinical decision. The controversial Provenge discussion is another reason to distinguish a demand for independent review from proof that a treatment is harmful.

The most careful reading is not that every man should refuse PSA testing. It is that routine screening should not be treated as self-evidently beneficial, and that any decision should account for personal risk, uncertainty, possible follow-up, and treatment harms. The book reflects evidence and guidelines discussed in 2014, so its claims should not be mistaken for current medical advice. Its durable contribution is a standard for evaluating screening: ask whether the entire pathway improves meaningful outcomes, not merely whether the test detects something sooner.

Summary in 30 Seconds
PSA measures a protein made by prostate tissue, not cancer itself. Benign conditions can raise the reading, and no single cutoff cleanly distinguishes cancer from no cancer. Screening may find slow-growing tumors that would never threaten life, while biopsies and treatment can cause lasting harm. Earlier diagnosis can improve survival statistics without extending life. Meaningful comparisons should track deaths, quality of life, and costs, with uncertainty and alternatives discussed before testing.
Contains spoilers

Last updated:

Report Issue

Review Summary

4.49 out of 5
Average of 115 ratings from Goodreads and Amazon.

The Great Prostate Hoax receives mostly positive reviews, with readers praising its eye-opening information about PSA testing and prostate cancer treatment. Many recommend it as essential reading for men over 40. Reviewers appreciate the author's credibility as the discoverer of PSA and his economic analysis of the prostate cancer industry. Some criticize the book's repetitiveness and lack of alternative treatment suggestions. A few readers disagree with the author's stance, believing PSA testing saved their lives. Overall, the book is seen as informative and thought-provoking, challenging conventional medical practices.

Your rating:
4.62
141 ratings
Want to read the full book?

Glossary

Prostate-specific antigen (PSA)

prostate protein measured in blood

A protein produced by prostate tissue that helps liquefy semen. A blood test measures the small amount that enters the bloodstream. The book emphasizes that PSA can be present or elevated in normal, enlarged, inflamed, and cancerous prostates, so a result alone cannot diagnose prostate cancer or reliably distinguish aggressive disease from slow-growing disease.

Four cruxes

four limits of PSA screening

Ablin’s shorthand for four reasons he argues against routine PSA screening of healthy men: PSA is not specific to cancer, no single reading reliably identifies cancer, the test cannot distinguish indolent from aggressive tumors, and prostate cancer becomes common with age. Together, these limitations make a positive result an uncertain basis for biopsy or treatment.

turtle and rabbit

indolent versus aggressive tumors

Ablin’s metaphor for the different courses prostate cancer can take. The turtle represents a slow-growing tumor that may never threaten a man’s life; the rabbit represents a rapidly progressing tumor that may spread beyond the prostate. The book argues that PSA cannot reliably tell which course a diagnosed tumor will follow.

active surveillance

monitoring without immediate treatment

A management approach for selected prostate cancers in which the patient is followed through examinations and tests rather than treated immediately. Treatment may be considered if evidence suggests the cancer is changing. In the book, active surveillance is presented as an alternative to the assumption that a prostate cancer diagnosis requires prompt surgery or radiation.

overdiagnosis

finding disease that would not harm

The detection of an abnormality that meets the medical definition of cancer but would never cause symptoms or death during a person’s lifetime. The book argues that PSA screening can uncover many slow-growing prostate tumors, and that diagnosis may lead to anxiety and treatment harms even when the tumor would not have affected the patient.

lead-time bias

earlier diagnosis, unchanged lifespan

A statistical distortion that occurs when an illness is detected earlier, making the measured time from diagnosis to death longer even though the person does not live longer. Ablin uses this concept to explain why improved survival after prostate cancer diagnosis does not, by itself, prove that PSA screening prevents deaths.

PIVOT

surgery versus observation trial

The Prostate Cancer Intervention versus Observation Trial compared radical prostatectomy with observation for men with localized prostate cancer. The book cites its finding that surgery did not significantly reduce overall or prostate cancer mortality compared with observation through at least 12 years of follow-up. Ablin uses the study to question automatic treatment after diagnosis.

gizmo idolatry

assuming technology means better care

A term discussed in the book for the implicit belief that a more technological procedure or device is inherently superior to a less technological option, even without strong evidence of better results. Ablin applies it to costly prostate cancer treatments such as proton-beam therapy and robotic surgery when their promised advantages are not clearly demonstrated.

Provenge

personalized prostate cancer immunotherapy

The brand name for sipuleucel-T, an immune-based treatment approved for some men with advanced prostate cancer. The patient’s white blood cells are collected, processed, and returned in a series of infusions. The book discusses the treatment’s reported survival benefit and a disputed critique of the control group’s cell handling, which Ablin argues merits independent scrutiny.

IMPACT trial

Provenge survival study

A clinical trial of Provenge in men with advanced prostate cancer that compared treatment with a control group. As described in the book, the study reported about 4.1 months longer survival for men receiving Provenge. Researcher Marie Huber later questioned whether differences in the control group’s cell handling could have influenced the result; that interpretation remains disputed in the book.

About the Author

Richard J. Ablin is a professor of pathology and the discoverer of the PSA (prostate-specific antigen) molecule in 1970. He has spent decades advocating for the proper use of PSA testing and warning against its overuse in prostate cancer screening. Ablin is critical of the prostate cancer industry's profit-driven approach and has worked to educate the public about the limitations and potential harms of PSA testing. His expertise in the field and firsthand knowledge of PSA's discovery give him unique authority on the subject. Ablin's work extends beyond this book, including writing a widely-read New York Times column and producing a documentary on the topic.

Download PDF

To save this The Great Prostate Hoax summary for later, download the free PDF. You can print it out, or read offline at your convenience.
Download PDF
File size: 0.37 MB     Pages: 18

Download EPUB

To read this The Great Prostate Hoax summary on your e-reader device or app, download the free EPUB. The .epub digital book format is ideal for reading ebooks on phones, tablets, and e-readers.
Download EPUB
File size: 1.45 MB     Pages: 20
Want to read the full book?
Follow
Listen
Home
Swipe
Library
Get App
Try Full Access for 3 Days
Listen, bookmark, and more
Compare Features Free Pro
📖 Read Summaries
Read unlimited summaries. Free users get 3 per month
🎧 Listen to Summaries
Listen to unlimited summaries in 40 languages
—
❤️ Unlimited Bookmarks
Free users are limited to 4
—
📜 Unlimited History
Free users are limited to 4
—
📥 Unlimited Downloads
Free users are limited to 1
—
Risk-Free Timeline
Today: Get Instant Access
Listen to full summaries of 26,000+ books. That's 12,000+ hours of audio!
Day 2: Trial Reminder
We'll send you a notification that your trial is ending soon.
Day 3: Your subscription begins
You'll be charged on Nov 25,
cancel anytime before.
Consume 2.8× More Books
2.8× more books Listening Reading
Our users love us
1M+ readers
Trustpilot Rating
TrustPilot
4.6 Excellent
This site is a total game-changer. I've been flying through book summaries like never before. Highly, highly recommend.
— Dave G
Worth my money and time, and really well made. I've never seen this quality of summaries on other websites. Very helpful!
— Em
Highly recommended!! Fantastic service. Perfect for those that want a little more than a teaser but not all the intricate details of a full audio book.
— Greg M
Save 62%
Yearly
$119.88 $44.99/year/yr
$3.75/mo
Monthly
$9.99/mo
Start a 3-Day Free Trial
3 days free, then $44.99/year. Cancel anytime.
Unlock a world of fiction & nonfiction books
26,000+ books for the price of 2 books
Read any book in 10 minutes
Discover new books like Tinder
Request any book if it's not summarized
Read more books than anyone you know
#1 app for book lovers
Lifelike & immersive summaries
30-day money-back guarantee
Download summaries in EPUBs or PDFs
Cancel anytime in a few clicks

Why one summary?

Scanner
Find a barcode to scan

⭐
⭐
⭐
We have a special gift for you
Open
38% off
DISCOUNT FOR YOU
⭐
⭐
⭐
$79.99
$49.99/year
Only $4.16 per month
Continue
2 taps to start, super easy to cancel
Settings
General
Widget
Loading...